Department of Neurology, Hokkaido University, Graduate School of Medicine, N15W7, Kita-ku, Sapporo, 060-8638, Japan.
J Neurol. 2012 Sep;259(9):1913-22. doi: 10.1007/s00415-012-6439-0. Epub 2012 Feb 17.
Previous studies have identified several genetic loci associated with the development of familial inclusion body myopathy. However, there have been few genetic analyses of sporadic inclusion body myositis (sIBM). In order to explore the molecular basis of sIBM and to investigate genotype-phenotype correlations, we performed a clinicopathological analysis of 21 sIBM patients and screened for mutations in the Desmin, GNE, MYHC2A, VCP, and ZASP genes. All coding exons of the five genes were sequenced directly. Definite IBM was confirmed in 14 cases, probable IBM in three cases, and possible IBM in four cases. No cases showed missense mutations in the Desmin, GNE, or VCP genes. Three patients carried the missense mutation c.2542T>C (p.V805A) in the MYHC2A gene; immunohistochemical staining for MYHC isoforms in these three cases showed atrophy or loss of muscle fibers expressing MYHC IIa or IIx. One patient harbored the missense mutation c.1719G>A (p.V566M) in the ZASP gene; immunohistochemical studies of Z-band-associated proteins revealed Z-band abnormalities. Both of the novel heterogeneous mutations were located in highly evolutionarily conserved domains of their respective genes. Cumulatively, these findings have expanded our understanding of the molecular background of sIBM. However, we advocate further clinicopathology and investigation of additional candidate genes in a larger cohort.
先前的研究已经确定了几个与家族性包涵体肌病发展相关的遗传位点。然而,对散发性包涵体肌病(sIBM)的遗传分析却很少。为了探讨 sIBM 的分子基础并研究基因型-表型相关性,我们对 21 例 sIBM 患者进行了临床病理分析,并筛选了 Desmin、GNE、MYHC2A、VCP 和 ZASP 基因的突变。直接对这五个基因的所有编码外显子进行测序。14 例确诊为 IBM,3 例可能为 IBM,4 例可能为 IBM。在 Desmin、GNE 或 VCP 基因中未发现错义突变。3 例患者携带 MYHC2A 基因 c.2542T>C(p.V805A)错义突变;这 3 例患者的 MYHC 同工型免疫组织化学染色显示 MYHC IIa 或 IIx 表达的肌纤维萎缩或缺失。1 例患者携带 ZASP 基因 c.1719G>A(p.V566M)错义突变;Z 带相关蛋白的免疫组织化学研究显示 Z 带异常。这两个新的异质突变都位于各自基因高度进化保守的区域。总的来说,这些发现扩展了我们对 sIBM 分子背景的理解。然而,我们主张在更大的队列中进一步进行临床病理和对其他候选基因的研究。